Table 3.
Prevalence of risk factors for anthracycline-related left ventricular dysfunction in patients with AML
| AML cohort | Age group | Comorbidity | Prevalence, % |
|---|---|---|---|
| Danish National Leukemia Registry*41 | Median age 59 y (range: 15-83 y) | Myocardial infarction | 24.6 |
| Chronic heart failure† | 12.5 | ||
| Peripheral vascular disease | 21.9 | ||
| Moderate to severe renal disease† | 19.2 | ||
| MD Anderson Cancer Center (HCT-CI validation cohort)*45 | >60 y | Cardiac disease (chronic heart failure, coronary artery disease, valvular dysfunction) | 41.0 |
| Prior cerebrovascular accident | 6.0 | ||
| Comprehensive Cancer Center of Wake Forrest University*44 | ≥60 y | Cardiac disease† | 12.5 |
| Renal disease† | 15.3 | ||
| Surveillance, Epidemiology, and End-Results Medicare linked database45 | >65 y; mean age 77.26 y ± 6.96 | Chronic heart failure‡ | 21.5 |
| Cerebrovascular disease‡ | 18.2 | ||
| Prior myocardial infarction‡ | 8.2 |
*
Includes only patients preselected to receive intensive chemotherapy.
†
As defined by Charlson Comorbidity Index (chronic heart failure defined by symptomatic dyspnea; chronic renal disease defined as creatinine >3 mg/dL).
‡
Based on International Classification of Diseases-9- and Current Procedural Terminology-4 codes.